{"data":{"type":"company_profile","id":131037,"entity_id":"wefunder:company:131037","attributes":{"canonical_url":"https://wefunder.com/assured.med.supply","generated_at":"2026-06-25T18:31:02Z","updated_at":"2026-06-25T05:02:19Z","entity_ids":{"company":"wefunder:company:131037","slug":"wefunder:company_slug:assured.med.supply"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-25T18:31:02Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-25T05:02:19Z","as_of":"2026-06-25T18:31:02Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-25T05:02:19Z","as_of":"2026-06-25T18:31:02Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-04-15T16:04:30Z","as_of":"2026-06-25T18:31:02Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-04-15T16:04:30Z","as_of":"2026-06-25T18:31:02Z","confidence":"medium"}}},"company":{"id":131037,"entity_id":"wefunder:company:131037","slug":"assured.med.supply","name":"Assured Med Supply (AMS.AI)","tagline":"AI Co-Pilot that could transform the $1.3 Trillion Medical Distribution Market","story":"During our first three years working in the traditional medical supply industry, Assured Med Supply (AMS) achieved an annual growth rate of over 100% year-on-year without any outside financing or debt. We secured partnerships with top hospitals (ranked in the U.S. top 100) and multiple large Fortune 500 clients.As seasoned medical industry insiders with a rare blend of tech expertise, we uncovered a major gap in the $1.3 trillion medical distribution market. Recognizing the immense potential to address the #2 biggest expense for hospitals, we recently made a decisive pivot into AI. This strategic leap empowers us to eliminate critical inefficiencies in the medical supply chain, leveraging our proven healthcare success and extensive client base. As a pure-play AI healthcare company with an elite AI team, we are ready to lead the medical supply industry into a new era of AI-driven innovation.Sources: Harvard Business Review, Navigant, Medical Economics, Chief HealthcareWhile growing our existing medical supply business, we realized that our past successes and AI experience uniquely position us to address many of these medical supply challenges with AI. Since 2023, we have been operating as a pure AI company, fully focused on developing technology such as:AI Conversational Chat Interface – hospital and clinic buyers can communicate purchasing needs in real-time and receive immediate feedback for decision-making based on an AI-powered natural human language chat interfaceDynamic AI-Powered Marketplace – buyers can view available inventory across an aggregated set of pre-qualified vendors, receive automated price comparisons, and even benefit from dynamic group buying algorithms to further reduce costsVisualization \u0026amp; Analysis AI Dashboards – buyers can review key information such as product substitution options and predictive analysis on delivery schedules and inventory pipelines to make better decisions on purchasing and inventory planningEnterprise Integration – our platform integrates easily with dominant legacy ERP systems like SAP and major purchasing gateway systems like GHX to ensure ease of adoption for our healthcare customersFuture projections are not guaranteed.Source: PWCDistinct from many other startups, we have shown that we can successfully grow our Company. We also have several years of experience in the medical supply business space, and the added advantage of already having some of the world’s leading hospitals and medical companies as our customers. We plan to leverage our prior success and unique experience in medical supplies, AI chatbots, messaging, logistics, and marketplaces for a best-in-class solution.The Revenue ModelAI–SaaS Subscriptions – hospital buyers pay an annual subscription fee for the intelligent AI marketplace, AI purchasing assistant, and smart analyticsAI Marketplace Platform Fees – medical vendors pay a percentage of the value of any sales they conduct via the marketplace platformWe aim to achieve over $20M of total revenue in the first two full years of our new AI platform operation, and project that we will scale to over $100M in 2028Current Round Offering: $1,234,925","location":"Los Angeles, CA","website":"https://www.amshealth.ai","total_amount_raised":1234925,"total_investors":286,"is_funded":true,"is_active":true,"quality_score":2,"related_urls":["https://wefunder.com/assured.med.supply","https://www.amshealth.ai"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/131037/xxl_blob.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/131037/large_blob.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/131037/standard_blob.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/131037/standard_blob.jpg"},"links":{"company_url":"https://www.amshealth.ai"},"highlights":[{"id":75537,"name":"repeat_founder","url":"repeatfounder","presentable_name":"Repeat Founder","description":"Started a prior company with $2M+ in funding or revenue","image_url":"https://uploads.wefunder.com/2021/profile-highlights-replay.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Transforming the Future of the $1.3 Trillion Medical Distribution Industry with AI"},{"index":2,"claim_id":"claim-fact-2","value":"Self-made success story: Prior to pivoting to AI, our medical supply business achieved $5M+ revenue"},{"index":3,"claim_id":"claim-fact-3","value":"Our medical supply business had year-on-year growth of over 100% with no outside debt or investment"},{"index":4,"claim_id":"claim-fact-4","value":"Al-powered healthcare solutions are projected to save Americans $150B annually by 2026"},{"index":5,"claim_id":"claim-fact-5","value":"Secured key distribution partnerships, including SIEMENS ($100B+ market cap)"},{"index":6,"claim_id":"claim-fact-6","value":"Our primary customers include the #2-ranked hospital in America and other top-100 U.S. hospitals"},{"index":7,"claim_id":"claim-fact-7","value":"Clients include the world's 2nd largest healthcare company, Thermo Fisher + 5 Fortune-500 companies"},{"index":8,"claim_id":"claim-fact-8","value":"Leadership team featured on Forbes, CNBC, TED Talk, TechCrunch, and other major media"}],"team":[{"id":5170420,"entity_id":"wefunder:company_role:5170420","user_entity_id":"wefunder:user:4460748","role":"founder","name":"Roy Malkin","title":"Co-Founder, CEO","bio":"Tech entrepreneur. 10+ years in healthcare. Helped build companies with exits to Amazon \u0026amp; Cisco. Co-founded Red Swan CRE (now $9B in assets) and led award-winning tech startups. Fortune 500 experience at Disney \u0026amp; Liberty Media. MBA from UCLA, AI at MIT.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5170420/square_blob.jpg?1724273752","profile_url":"https://wefunder.com/roy.malkin","personal_url":"https://wefunder.com/assuredmedsupply","linkedin_url":"https://linkedin.com/in/roymalkin/","related_urls":["https://wefunder.com/roy.malkin","https://wefunder.com/assuredmedsupply"]},{"id":4220288,"entity_id":"wefunder:company_role:4220288","user_entity_id":"wefunder:user:4313029","role":"founder","name":"Gary Lipsky","title":"Co-Founder, COO","bio":"Tech founder and leader with 20+ yrs in tech, strategy \u0026amp; finance. Drove innovation \u0026amp; operational excellence for enterprise, government, and startup clients. Built products automating complex workflows. MBA from GW","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/4220288/square_blob.jpg?1724191503","profile_url":"https://wefunder.com/gary.lipsky","linkedin_url":"https://linkedin.com/in/garylipsky","related_urls":["https://wefunder.com/gary.lipsky"]},{"id":5168711,"entity_id":"wefunder:company_role:5168711","user_entity_id":"wefunder:user:2894484","role":"founder","name":"Don Oparah","title":"Co-Founder, Advisor","bio":"Don, a TED speaker with a Cambridge (UK) PhD in Computer Science, has an illustrious 25+ years in tech. He has worked with 20+ startups that have gained VC backing, Fortune 500 acquisitions, Inc. 5000 listings, and TechCrunch Disrupt victories.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5168711/square_blob.jpg?1726025377","profile_url":"https://wefunder.com/donoparah1","linkedin_url":"https://linkedin.com/in/donoparah","related_urls":["https://wefunder.com/donoparah1"]},{"id":3794513,"entity_id":"wefunder:company_role:3794513","role":"employee","name":"Vyacheslav Kungurtsev","title":"Chief AI Scientist","bio":"Vyacheslav is a machine learning \u0026amp; AI wizard with a Ph.D. from UC, San Diego, and a Math degree from Duke. He has made a strong impact in Generative AI with his landmark publications and AI algorithm consulting for enterprises and the government.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3794513/square_blob.jpg?1724090276","linkedin_url":"https://linkedin.com/vyacheslav-kungurtsev-3694962a","related_urls":[]},{"id":3794572,"entity_id":"wefunder:company_role:3794572","role":"employee","name":"Alejandro Narancio","title":"CTO","bio":"Alejandro has 20+ years in tech and has been a leader in AI \u0026amp; blockchain. He led top projects focused on the traceability of medical prescriptions. He holds dual degrees from the University of Uruguay in Computer Science and Engineering.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3794572/square_blob.jpg?1724090276","linkedin_url":"https://linkedin.com/alejandronarancio","related_urls":[]}],"featured_investors":[{"id":9655,"entity_id":"wefunder:company_investor_profile:9655","investor_profile_id":3935060,"investor_profile_entity_id":"wefunder:investor_profile:3935060","subject_entity_id":"wefunder:user:4444306","name":"Ostapchuk Liliia","role_title":"","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png","profile_url":"https://wefunder.com/ostapchuk.liliia","endorsement_quote":"Investing in Assured Med Supply means joining an AI revolution in healthcare supply chain management - a $1 Trillion market with high margins and long- term potential. Their AMS.AI platform solves a major pain point for hospitals: huge purchasing and reporting inefficiencies in supply chain. It tackles hospitals' second-largest expense, which can exceed $600M per hospital. The team's track record is stellar. Their last startup they founded is now a world leader for their market and manages $9B in assets. Previously, they built a supply chain startup ranked the fastest-growing in America by Inc. 5000. This expertise, combined with cutting-edge AI capabilities, positions this team to transform hospital supply chains. Beyond profits, there's a huge impact investment angle they're not advertising. AMS.AI is not just made for the biggest most successful hospitals but can directly prevent smaller rural hospitals from shutting down (Most people don't realize 30% are in danger of shut down due to financial issues), saving healthcare for millions of people and saving lives. As a seasoned investor and myself a co-founder of a successful Silicon Valley tech company, I rarely see opportunities combining proven leadership, game-changing technology, and massive market need like this. Assured Med Supply isn't just a smart investment; it's a chance to be part of a healthcare \u0026amp; AI revolution.","endorsement_name":"","investment_total":50000,"investment_info":"Invested $50,000 this round","is_lead_investor":true,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/ostapchuk.liliia"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":25,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":80496,"entity_id":"wefunder:fundraise:80496","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"custom","security_type":"custom","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"minimum_target":"50000.0","maximum_target":"1234925.0","funding_started_at":"2024-08-16T19:12:56Z","funding_closed_at":"2025-05-01T04:01:02Z","auto_close_at":"2025-05-01T03:59:59Z"},{"id":80497,"entity_id":"wefunder:fundraise:80497","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":1234925.0,"minimum_target":"50000.0","maximum_target":"1234925.0","funding_started_at":"2023-04-12T19:17:06Z"}],"latest_fundraise":{"id":80496,"entity_id":"wefunder:fundraise:80496","state":"successful","offering_type":"4(a)(6)","structure":"custom","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2024-08-16T19:12:56Z","funding_closed_at":"2025-05-01T04:01:02Z","terms":{"eb":null,"nb":null,"txt":null}},"recent_posts":[],"q_and_a":[{"id":309379,"entity_id":"wefunder:comment:309379","question":"Are we going to get any updates on what is going on with AMS? Maybe an AMA? I haven't heard anything in over as month","author_name":"Michael Bradley","votes":4,"created_at":"2025-06-08T17:02:34Z","canonical_url":"https://wefunder.com/assured.med.supply#question-309379","answers":[]},{"id":290631,"entity_id":"wefunder:comment:290631","question":"Do you have any patents? Why did your revenue go down in 2023 compared with 2022?","author_name":"Grigore B. Hreniuc","votes":4,"created_at":"2024-08-16T21:40:25Z","canonical_url":"https://wefunder.com/assured.med.supply#question-290631","answers":[{"id":290699,"entity_id":"wefunder:comment:290699","answer":"Grigore, thank you very much for your 2 great questions and interest in AMS.AI / Assured Med Supply. Our proprietary technology will focus on highly accurate algorithms for AI-powered medical product selection and AI vendor matching, supported by proprietary data, all of which we will protect as trade secrets. Like many generative AI startups, we are prioritizing a trade secrets strategy over patents at this stage to focus our resources on developing platforms that hospitals—which require the highest accuracy in their AI solutions—will find indispensable. This approach aligns with the broader trend for generative AI startups, where the need for speed, flexibility, and confidentiality in a rapidly evolving field often makes trade secrets more practical than patents. That being said, we will be exploring filing patents shortly after our raise, related to how our AI (1) identifies substitutes, (2) facilitates unique vendor matching, and (3) generates unique hospital reporting through a distinctive UI. In 2023, we fully transitioned to a pure AI company. While this may sacrifice short-term revenue, it strategically positions us to leverage our strong healthcare customer base and tap into the massive $1.3 trillion medical distribution market in a new and potentially far more profitable way. We believe the upside of being a pure AI company is significantly greater than in our traditional business, as demonstrated to us by the amazing success of other generative AI companies like OpenAI and Anthropic.","author_name":"Roy Malkin","votes":1,"created_at":"2024-08-18T15:26:02Z"}]},{"id":303101,"entity_id":"wefunder:comment:303101","question":"Maybe I missed it, but what are the exit plans? Thanks!","author_name":"Anthony Hamilton","votes":3,"created_at":"2025-02-28T00:29:40Z","canonical_url":"https://wefunder.com/assured.med.supply#question-303101","answers":[{"id":303237,"entity_id":"wefunder:comment:303237","answer":"Great question. Here are our 2 major exit plans: 1) Acquisition by a major healthcare, AI, or logistics company – Given our partnerships and the scale of the problem in a $1.3T market we’re solving, a strategic acquisition is a strong possibility. 2) IPO – My last co-founded company is considering an IPO next year, and AMS AI has the potential to follow a similar trajectory, at AMS AI, we will be targeting a public offering on Nasdaq once we reach significant key revenue and market adoption milestones","author_name":"Roy Malkin","votes":0,"created_at":"2025-03-01T12:37:04Z"}]},{"id":291784,"entity_id":"wefunder:comment:291784","question":"Where does your co-pilot sit? You call it an AI SaaS, so is it a duplicative system that administrators need to access, or does it fully integrate into common purchasing platform? A slightly different question, where exactly do you play in the buying value chain? Given the percentage of the U.S. healthcare system that is locked into exclusive GPO buying contracts, are you collaborating with the big GPOs? Your competitive chart would seem to imply not (eg Vizient). Is your ultimate strategy to create your own GPO network? For background, I've spent the last 15 years in med tech. Of the $1.3T in medical purchases, 98% flow through GPOs (with 76% of them being completely exclusive or categorically exclusive). If I strip away the AI buzz factor, I'm trying to ascertain where the opportunity is. Your addressable market size would seem to be the 2% not tied to GPOs. Am I missing something?","author_name":"Lance Longwell","votes":3,"created_at":"2024-09-06T03:29:45Z","canonical_url":"https://wefunder.com/assured.med.supply#question-291784","answers":[{"id":291867,"entity_id":"wefunder:comment:291867","answer":"Hi Lance, Thank you for your thoughtful and insightful question. We’d love to have someone with your healthcare industry experience as part of our AMS.AI / Assured Med Supply. investor base, providing valuable insights. To address your points, we initially plan to launch as a standalone AI platform designed to assist key hospital decision-makers in making more informed and efficient purchasing decisions. Think of it like how AI tools are revolutionizing financial trading for banks and hedge funds—processing vast amounts of data in real-time to make smarter predictions in micro-seconds and reduce risks. Our system will support procurement and supply chain teams similarly, optimizing workflows and reducing inefficiencies. As we refine our model and gain traction, we plan to integrate with existing ordering systems, or they may eventually become compatible with ours as we scale to become the industry standard. We’re following Peter Thiel’s philosophy of building a \"beachhead\" by starting with a targeted, solvable problem—such as medical supply shortages—and expanding from there. Our slide, \"Our Vision for Growth,\" clearly outlines how we will strategically evolve in parallel to how other big companies started. By focusing on this specific need first, we’ll gain traction and grow from that initial foothold to dominate broader segments of the $1.3T medical distribution market. Much like entrepreneurs such as Elon Musk \u0026amp; Jeff Bezos, we are applying first principles thinking to disrupt this industry. We started by dissecting the core problems in healthcare procurement—hospitals are highly inefficient when managing shortages, finding alternative vendors, and frequently overpaying for essential supplies. On top of that, these supplies often arrive late, especially during disruptions like those experienced during the COVID-19 pandemic. Many hospitals experienced significant shortfalls from their GPO contract suppliers during that time and are now focused on building more resiliency into their supply chains. When there is another \"black swan\" event (war, pandemic, instability in a key country that supplies medical equipment. major product recall.), AI platform like ours can quickly shift purchasing/new vendors rapidly, and Hospitals cannot afford to wait on how such events play out as lives are at stake. Even within the GPO system, inefficiencies persist, and we believe AI can drive significant improvements in this area. Our initial focus will be on addressing the 20% of medical supplies currently in shortage and areas not fully covered by GPOs. This market alone likely represents hundreds of billions of dollars, and we see immense potential here. We remain open to working with GPOs in the future. The bottom line is that we’re creating real value for hospitals by offering a quick, scalable solution to reduce shortages and access non-GPO products. As we scale, hospitals will have an efficient alternative for managing procurement, and larger institutions may even explore factory-direct options or other cost-saving measures. This market is enormous, and AI is one of the keys to unlocking its potential. Additionally, if we feel it would maximize value for the company and investors, the option of creating our own specialized AI-powered GPO based on the significant data and insights we will generate remains a potential strategic angle for our venture over the longer term. We’d be thrilled to have you join us as an investor on this exciting journey.","author_name":"Roy Malkin","votes":1,"created_at":"2024-09-07T17:28:19Z"}]},{"id":307527,"entity_id":"wefunder:comment:307527","question":"Do you already have an app development team in place?","author_name":"Majed Mahmood","votes":2,"created_at":"2025-05-05T19:19:50Z","canonical_url":"https://wefunder.com/assured.med.supply#question-307527","answers":[]},{"id":306487,"entity_id":"wefunder:comment:306487","question":"Are you still accepting investments now that you are oversubscribed or are you taking as much money as possible until closing date?","author_name":"Matthew Junkin","votes":2,"created_at":"2025-04-21T18:06:55Z","canonical_url":"https://wefunder.com/assured.med.supply#question-306487","answers":[]},{"id":305537,"entity_id":"wefunder:comment:305537","question":"Where is the AI product now? Is there an MVP, a working prototype, or customer pilots? What are short-term revenue milestones? When do you expect first paying AI clients? How will funds from this round be used? (Breakdown of development, hiring, marketing) What does success look like in 6–12 months? (Customers, revenue, tech readiness) What is your competitive moat? (What keeps others from copying this?)","author_name":"Alyssia Crump","votes":2,"created_at":"2025-04-07T19:02:27Z","canonical_url":"https://wefunder.com/assured.med.supply#question-305537","answers":[]},{"id":303494,"entity_id":"wefunder:comment:303494","question":"Thanks for taking my call yesterday.","author_name":"Anthony Hamilton","votes":1,"created_at":"2025-03-05T15:25:07Z","canonical_url":"https://wefunder.com/assured.med.supply#question-303494","answers":[{"id":303619,"entity_id":"wefunder:comment:303619","answer":"👍","author_name":"Roy Malkin","votes":0,"created_at":"2025-03-06T20:35:18Z"}]},{"id":301680,"entity_id":"wefunder:comment:301680","question":"Will you and your team be giving updates (monthly, weekly) on the progress you are making in trying to build this project? I am extremely bullish on this concept for so many reasons and am ready to invest more money in the coming weeks. If people haven't noticed - there has been a dramatic change (in the last several weeks) in the way our government is focusing on waste, fraud, and inefficiency on how they spend the taxpayers money. The healthcare industry is a prime example. I also believe this project is recession-proof. The timing could not be better for this project. Can't wait to hear your updates on how the project is progressing. Thanks","author_name":"Michael Bradley","votes":1,"created_at":"2025-02-06T15:31:23Z","canonical_url":"https://wefunder.com/assured.med.supply#question-301680","answers":[{"id":301725,"entity_id":"wefunder:comment:301725","answer":"Great question, as always, Michael. We’re planning to host a live Q\u0026amp;A between mid-March and mid-April, which might be the best forum to discuss all our progress in more detail. We will make an announcement ahead of the date. That being said, the recent DeepSeek copying of OpenAI is making the entire U.S. AI industry super cautious about what they release publicly and how soon before any new feature releases. One advantage we have is that U.S. hospitals are highly unlikely to work with non-U.S. AI companies due to the sensitivity of their data. In contrast, OpenAI operates a consumer model where end users are generally less concerned about data privacy from a foreign competitor. Regarding your DOGE comment, we’ve positioned ourselves as DOGE for hospitals before DOGE was even a concept! It is recession-proof, in the sense that Hospitals look to cut costs even more during a recession, and they spend on supplies no matter what happens in economy.","author_name":"Roy Malkin","votes":1,"created_at":"2025-02-07T01:38:47Z"}]},{"id":301599,"entity_id":"wefunder:comment:301599","question":"Has the transformer been trained with your own funds on proprietary data or you a second layer APP？ AI is still at the beginning and the mainstream narrative mentions that SAAS model is not future proof: what your hedges?","author_name":"Mirko Turrina","votes":1,"created_at":"2025-02-05T07:47:34Z","canonical_url":"https://wefunder.com/assured.med.supply#question-301599","answers":[{"id":301604,"entity_id":"wefunder:comment:301604","answer":"Our transformer is trained on proprietary data, ensuring a unique and competitive edge. While we leverage foundational models where it makes sense (for speed, cost, and efficiency to go to market), we’re not just a second-layer app—we enhance AI with exclusive datasets and domain-specific optimizations. Regarding your SaaS question, we \"hedge\" these risks not only by embedding AI directly into critical healthcare workflows, but also by adopting a hybrid revenue model beyond subscriptions, and forming deep industry partnerships but also by creating lock-in through a marketplace model with strong network effects. Our platform is an increasingly integrated AI ecosystem for the healthcare supply chain that becomes better and more indispensable over time the more its used. Just like launching a 30% better software version of eBay or Facebook marketplace wouldn’t instantly shift its user base to a new platform, our marketplace ensures that once vendors and buyers are engaged, the increasing value of the network makes it difficult to replicate or disrupt. As a team, we’ve built multiple successful marketplaces, facilitating billions of USD in transactions, and we are confident we can replicate our past success with a platform with long-staying power and scalability. The marketplace will be integrated in phases, ensuring a seamless transition and long-term adoption. Mirko, given your publicly stated commitment to making the world a better place, we would love to have you as a significant impact investor in AMS AI. Through our work in the medical industry and our goal of becoming a healthcare AI unicorn, we are actively helping rural hospitals cut costs and stay in business despite financial challenges—with 30% at risk of closure, leaving rural communities without timely access to critical care, which can have catastrophic consequences. Additionally, we are working to prevent life-saving procedure delays, like surgeries, caused by persistent medical supply shortages.","author_name":"Roy Malkin","votes":3,"created_at":"2025-02-05T12:22:31Z"}]},{"id":301505,"entity_id":"wefunder:comment:301505","question":"Can we still invest more money at the pre-raise valuation of 9M at a later date? Or do the terms change after the rolling close date on Feb 11th? Thanks","author_name":"Michael Bradley","votes":1,"created_at":"2025-02-03T22:46:12Z","canonical_url":"https://wefunder.com/assured.med.supply#question-301505","answers":[{"id":301527,"entity_id":"wefunder:comment:301527","answer":"Good question, Michael. The close date is set for April 29, 2025; as far as I know, the valuation remains the same. Investing early rather than waiting on the sidelines until the last minute is in everyone's best interest. Those who move now help fuel the momentum of other investors coming in—and stand to gain the most from it as we can bring more features to market earlier and push as hard as we can to get maximum adoption of our product with hospitals. AI is capital intensive, but as you saw with Palantir's earnings announcement today and OpenAI's $300B+ valuation last week, it's worth it, and we only began to scratch the surface of the ROI investors can expect from AI companies.","author_name":"Roy Malkin","votes":0,"created_at":"2025-02-04T03:20:42Z"}]},{"id":336004,"entity_id":"wefunder:comment:336004","question":"Hello Roy, do you have any updates?","author_name":"Gunter Van Den Bossche","votes":0,"created_at":"2026-06-20T02:49:18Z","canonical_url":"https://wefunder.com/assured.med.supply#question-336004","answers":[]},{"id":310950,"entity_id":"wefunder:comment:310950","question":"i invested on Feb 9, 2025 $1,000 but i do not see the number of shares ? Regards Richard Clement","author_name":"Richard Clement","votes":0,"created_at":"2025-07-07T22:37:30Z","canonical_url":"https://wefunder.com/assured.med.supply#question-310950","answers":[]},{"id":310949,"entity_id":"wefunder:comment:310949","question":"hello ! hope all is well what are your monthly revenues/expenses this first quarter ? Dr Richard Clement","author_name":"Richard Clement","votes":0,"created_at":"2025-07-07T22:24:25Z","canonical_url":"https://wefunder.com/assured.med.supply#question-310949","answers":[]},{"id":305123,"entity_id":"wefunder:comment:305123","question":"Hi Roy, when live Q\u0026amp;A will occur ?","author_name":"Ali Di","votes":0,"created_at":"2025-04-01T14:57:57Z","canonical_url":"https://wefunder.com/assured.med.supply#question-305123","answers":[]},{"id":305122,"entity_id":"wefunder:comment:305122","question":"Is there a roadmap? When will AMS.AI make profit?","author_name":"Gunter Van Den Bossche","votes":0,"created_at":"2025-04-01T14:44:29Z","canonical_url":"https://wefunder.com/assured.med.supply#question-305122","answers":[]},{"id":303624,"entity_id":"wefunder:comment:303624","question":"what is your current valuation","author_name":"Harish Damodhardas Asar","votes":0,"created_at":"2025-03-06T20:57:47Z","canonical_url":"https://wefunder.com/assured.med.supply#question-303624","answers":[{"id":303700,"entity_id":"wefunder:comment:303700","answer":"$ 9M Pre-Money","author_name":"Roy Malkin","votes":1,"created_at":"2025-03-07T22:35:11Z"}]},{"id":303623,"entity_id":"wefunder:comment:303623","question":"Hi, When is your fund raise closing.","author_name":"Harish Damodhardas Asar","votes":0,"created_at":"2025-03-06T20:57:16Z","canonical_url":"https://wefunder.com/assured.med.supply#question-303623","answers":[{"id":303625,"entity_id":"wefunder:comment:303625","answer":"Right now it is scheduled to close on April 29th, at this rate we may oversubscribe much sooner, so it would be great to have your backing while we are still taking new investments.","author_name":"Roy Malkin","votes":0,"created_at":"2025-03-06T21:02:43Z"}]},{"id":302584,"entity_id":"wefunder:comment:302584","question":"Hi Roy, isn't the healthcare supply market pretty closed with internal contracts only? Also, if it becomes an open market would logistics become an issue where you could lose time and savings? Thank you, Glenn","author_name":"Glenn Burney","votes":0,"created_at":"2025-02-19T19:31:14Z","canonical_url":"https://wefunder.com/assured.med.supply#question-302584","answers":[{"id":302618,"entity_id":"wefunder:comment:302618","answer":"Plenty of activity outside of contracts, even more so when a significant % of deals cannot be fulfilled contractually due to shortages.","author_name":"Roy Malkin","votes":0,"created_at":"2025-02-20T06:01:57Z"}]},{"id":301287,"entity_id":"wefunder:comment:301287","question":"Do you have any plans to engage with the US government? The waste and inefficiency in the Medicare/Medicaid systems is shocking and needs to be addressed ASAP.","author_name":"Michael Bradley","votes":0,"created_at":"2025-01-31T16:29:14Z","canonical_url":"https://wefunder.com/assured.med.supply#question-301287","answers":[{"id":301292,"entity_id":"wefunder:comment:301292","answer":"Great question. The answer is a resounding YES. You can think of AMS AI as the DOGE for hospitals—and soon for government healthcare operations as well. AMS is an approved government contractor with the DoD and has successfully executed deals with the VA healthcare system. Not only do we plan to do exactly what you're suggesting, but we also have the experience to execute it. Our COO has secured millions in successful government bids and contracts in the past, and we are actively looking to scale our D.C. operations. Additionally, we have leaders in Medicare/Medicaid efficiency coming on board soon as we plan to address waste and inefficiency in the Medicare/Medicaid systems at scale. Projections indicate that by 2032, healthcare spending could approach a massive 20% of the U.S. GDP; if this keeps growing to 25% or more, it can severely hurt the entire U.S. economy and crowd out all other basic needs we have. Additional funding will be critical for AMS AI expansion beyond hospitals, and we’d be grateful if you could quadruple down on your investment Michael! 🚀","author_name":"Roy Malkin","votes":2,"created_at":"2025-01-31T18:02:56Z"}]},{"id":299350,"entity_id":"wefunder:comment:299350","question":"What is the pre valuation on the raise as your unit per $$ is high? Have you successfully implemented the system at any healthcare system?","author_name":"Bret McManus","votes":0,"created_at":"2025-01-02T22:58:56Z","canonical_url":"https://wefunder.com/assured.med.supply#question-299350","answers":[{"id":299376,"entity_id":"wefunder:comment:299376","answer":"Thanks for your interest in AMS AI! Our pre-money valuation of just under $9M presents a rare opportunity in the booming AI sector, particularly given that the average seed-stage AI startup currently commands a $25M valuation (as of December 2024). With our founding team's proven track record of building a $200M+ company managing $9B in assets, we are uniquely positioned to deliver exceptional returns from this entry point. What makes this opportunity particularly compelling is our established position in healthcare AI - the fastest-growing segment of AI investment. While most healthcare startups spend 18-36 months trying to secure their first hospital relationships, AMS AI already has pre-built relationships as a vendor. In healthcare AI, this kind of access is equivalent to liquid gold - a competitive advantage that dramatically accelerates our path to scale. We're targeting the intersection of two massive markets: the $1.3T medical distribution sector and the $2.6T Agent AI market. With our enhanced platform version scheduled for release this quarter and hospital deployment targeted for early Q2, we're positioned for rapid scaling and value creation. This isn't just an investment in AI technology - it's an opportunity to back a proven team that has already solved one of healthcare's most challenging hurdles for healthcare startups: hospital access. By joining us now, you're investing in a company poised to redefine hospital operations while capturing significant market share in healthcare's AI transformation. With our experienced team, established hospital relationships, and imminent platform release, we invite you to be part of what Menlo Ventures identifies as one of the best opportunities in AI - healthcare, the fastest-growing AI segment. We invite you to seize this exclusive opportunity to join AMS AI as a seed investor before our upcoming much larger institutional VC round, positioning yourself at the forefront of our mission to revolutionize healthcare operations with AI.","author_name":"Roy Malkin","votes":4,"created_at":"2025-01-03T03:25:49Z"}]},{"id":299124,"entity_id":"wefunder:comment:299124","question":"Why are you abandoning your profitable business with millions in sales? You could continue the business and use the profits to fund the ai business. This screams incompetence.","author_name":"Jarod Rudisill","votes":0,"created_at":"2024-12-30T03:12:05Z","canonical_url":"https://wefunder.com/assured.med.supply#question-299124","answers":[{"id":299131,"entity_id":"wefunder:comment:299131","answer":"Thank you for your question—I’m happy to provide more context. The AI agent space we’ve pivoted to represents a $2.6 trillion market opportunity and is the most promising path forward for our company. We recognized this potential early, even before a leading research agency Gartner just now announced that the AI agent market is their #1 growth idea for 2025. While our traditional business was successful and we grew it without outside capital, it is incredibly time-intensive. Remaining competitive in that space while at the same time building a complex AI venture would require significant investments in warehousing and e-commerce infrastructure—efforts that would divert at least 75% of focus from creating something truly transformative in AI, where focused competitors dominate. Opportunity cost is key. Every minute spent growing a slower, traditional business is a minute not spent building a potential AI unicorn. It’s the same reason Elon Musk wouldn’t build an airplane to compete with Boeing—it might generate short-term cash, but it distracts from trillion-dollar opportunities like a Mars colony or robotics dominance. Similarly, Tesla shed its original groundbreaking Roadster, and Netflix moved away from its physical DVD business. Both companies made bold decisions to go all-in on their biggest opportunities, burn the ships—and succeeded massively as a result. We’ve witnessed many unicorns emerge in the last 1–2 years in AI, and every one of them has been all-in. The most successful companies focus entirely on their biggest opportunities, even at the expense of short-term profits. For us, going all-in is essential. Our prior startup grew to a ~$200M valuation this year, managing $9 billion in assets, and is likely on track to become a unicorn as a leader in CRE tokenization not just in USA, but across three continents. My passion for healthcare and the immense potential of AMS AI make anything less than full focus to create the next healthcare AI unicorn a waste of talent, opportunity, and potential shareholder value. Additionally, our established position as a vendor to major hospitals gives us a competitive advantage that new startups in the space cannot match. Hospitals are notoriously difficult to onboard as clients—it takes years to build these relationships. Our prior business enables us to leverage these connections as we develop transformative AI solutions, giving us a significant head start. We’ve done this before. Over the last few years, we co-founded and built a company now just one or two rounds away from unicorn status by following this exact strategy: raising a crowdfunding round that now has a very high ROI for shareholders, shedding non-essential business lines, and focusing entirely on the most fastest growing and biggest opportunity we can capture rapidly. It worked then, and we are confident it will work again. From Netflix to Tesla, the most successful companies succeed by focusing on their biggest opportunities, and that’s exactly what we’re doing. This pivot positions us to maximize impact, growth, and value for all stakeholders. On a personal note, Jarod I’m a client and a big fan of your bank, and I hope you’ll consider investing in our growth. We’d love to have you on this journey with us!","author_name":"Roy Malkin","votes":2,"created_at":"2024-12-30T05:58:21Z"}]},{"id":298887,"entity_id":"wefunder:comment:298887","question":"Regarding the use of funds, I note intended funds to be repaid to management. At this early stage of the game I question why I should enter as others exit at $10.51 that have considerably more knowledge than supplied, at a buck might be worth a shot. Anything else to consider ?","author_name":"Roger Evans","votes":0,"created_at":"2024-12-26T01:08:31Z","canonical_url":"https://wefunder.com/assured.med.supply#question-298887","answers":[{"id":298890,"entity_id":"wefunder:comment:298890","answer":"Thank you for your question, Roger, and for taking the investment process seriously—your diligence embodies the thoughtful approach we value in investors. No one from management is selling shares into this round or exiting their positions to profit personally on the current raise. Every dollar raised is being reinvested to further the company, accelerate product development, and drive valuation growth for all shareholders. At this stage, selling shares for the specific purpose of taking money off the table would be irrational for the management team and counterproductive, given the incredible momentum and prospects we’re experiencing from Fortune 500 and Unicorn industry leaders being added to our team to major companies like Cisco and Dell being interested in our project as strategic partners and/or investors. It would be similarly unlikely as Elon Musk selling SpaceX shares the day he successfully landed his rocket back on earth earlier this year. The market continues to validate our vision in exciting ways. The most renown market research firm, Gartner recently identified the AI Agent market that we operate in as the \"Top Tech Trend for 2025\", a sector valued at an astounding $2.6 trillion. Generative AI companies as a whole are seeing unprecedented growth—xAI, for instance, has reached a $40 billion valuation in just a year since its creation, while OpenAI is now valued at $157 billion only two years after its public launch. These trends highlight the immense opportunity in this space, and AMS AI (Assured Med Supply) is uniquely positioned to capitalize on it. If you missed out on broad-focused AI companies like xAI, Nvidia, or OpenAI, I firmly believe the best opportunities now lie with sector-focused AI companies like AMS AI. Unlike many AI startups, AMS has not only a world-class team but also a strong client base that includes some of the biggest hospitals and some of the most recognized Fortune 500 companies. A basic search I conducted recently suggests that our total valuation in this Wefunder round—an important metric far beyond nominal share price at this stage—is already 2.5 to 3 times lower than the average of AI companies at our stage across all sectors. Yet, we operate in what is arguably one of the highest-growing sectors within AI. Menlo Ventures recently confirmed that healthcare AI is leading the AI spend across all categories from 2023 to 2024, emphasizing the tremendous potential in our space. Again I strongly recommend that every investor does their due diligence on their own, I am just sharing what I observed with a basic search. As for the small reimbursement you mentioned, it represents less than half of 1% of the total amount raised and is strictly for minor expenses personally covered by management to support the company. For context, this negligible reimbursement is equivalent to what any individual on our management team might earn in one week of corporate work—yet we’ve chosen to dedicate our full time and energy to building AMS AI. Additionally, management has taken little to no salary throughout 2024, underscoring our commitment to maximizing the company’s growth and creating value for our shareholders. This level of dedication reflects our unwavering focus on the company’s success, ensuring every resource is strategically allocated to deliver transformative impact and maintain complete alignment with our shareholders. Finally, my previous company, which I co-founded, has delivered exceptional ROI for its shareholders to date, having also been originally raised through crowdfunding. That company now manages $9 billion in assets on its platform, is valued at approximately $200 million, and leads as the #1 company in global commercial real estate asset tokenization—one of the fastest-growing fields in the world, much like AI. I would not be dedicating myself to AMS AI like I am right now unless I was personally certain we are now building the next healthcare AI unicorn for the benefit of all our shareholders and the many hospitals \u0026amp; patients that we will help immensely with our platform. Roger, I truly hope to welcome you as an investor in 2024. Your insightful questions demonstrate your deep understanding of startup investing, and your track record of investing in strong healthcare and AI companies is impressive. It would be an honor to be backed by an investor with your level of expertise and vision.","author_name":"Roy Malkin","votes":1,"created_at":"2024-12-26T04:22:59Z"}]},{"id":292297,"entity_id":"wefunder:comment:292297","question":"What is the price per share/unit? According to your custom contract (subscription agreement), the price is $10.51 per unit but my Wefunder receipt is showing , $1 per unit.","author_name":"Efosa Amafidon","votes":0,"created_at":"2024-09-15T05:03:52Z","canonical_url":"https://wefunder.com/assured.med.supply#question-292297","answers":[{"id":292711,"entity_id":"wefunder:comment:292711","answer":"Thank you for your excellent question, Efosa, and for supporting us! I can confirm that the correct price per unit is indeed $10.51, as you read and is outlined in the subscription agreement. I’ve also double-checked with WeFunder regarding your specific issue with receipt, and they’re making/made all necessary internal adjustments on their end. Rest assured, everything will reflect accurately moving forward.","author_name":"Don Oparah","votes":0,"created_at":"2024-09-20T22:44:17Z"}]},{"id":290640,"entity_id":"wefunder:comment:290640","question":"Hi, are you all planning to maintain the current S-corp status of the company for tax purposes, so long as there are ultimately fewer than 100 shareholders?","author_name":"Lucas Selvidge","votes":0,"created_at":"2024-08-16T22:28:46Z","canonical_url":"https://wefunder.com/assured.med.supply#question-290640","answers":[{"id":290695,"entity_id":"wefunder:comment:290695","answer":"Lucas, thank you for asking and for your interest in AMS.AI / Assured Med Supply. Based on the legal and accounting advice we've received, we plan to switch to filing taxes as a C Corp close to or upon the finalization of the raise.","author_name":"Roy Malkin","votes":1,"created_at":"2024-08-18T14:27:33Z"}]}],"faq":[{"question":"Do you have any patents? Why did your revenue go down in 2023 compared with 2022?","answer":"Grigore, thank you very much for your 2 great questions and interest in AMS.AI / Assured Med Supply. Our proprietary technology will focus on highly accurate algorithms for AI-powered medical product selection and AI vendor matching, supported by proprietary data, all of which we will protect as trade secrets. Like many generative AI startups, we are prioritizing a trade secrets strategy over patents at this stage to focus our resources on developing platforms that hospitals—which require the..."},{"question":"Hi, are you all planning to maintain the current S-corp status of the company for tax purposes, so long as there are ultimately fewer than 100 shareholders?","answer":"Lucas, thank you for asking and for your interest in AMS.AI / Assured Med Supply. Based on the legal and accounting advice we've received, we plan to switch to filing taxes as a C Corp close to or upon the finalization of the raise."},{"question":"Where does your co-pilot sit? You call it an AI SaaS, so is it a duplicative system that administrators need to access, or does it fully integrate into common purchasing platform? A slightly different question, where exactly do you play in the buying value chain? Given the per...","answer":"Hi Lance, Thank you for your thoughtful and insightful question. We’d love to have someone with your healthcare industry experience as part of our AMS.AI / Assured Med Supply. investor base, providing valuable insights. To address your points, we initially plan to launch as a standalone AI platform designed to assist key hospital decision-makers in making more informed and efficient purchasing decisions. Think of it like how AI tools are revolutionizing financial trading for banks and hedge f..."},{"question":"What is the price per share/unit? According to your custom contract (subscription agreement), the price is $10.51 per unit but my Wefunder receipt is showing , $1 per unit.","answer":"Thank you for your excellent question, Efosa, and for supporting us! I can confirm that the correct price per unit is indeed $10.51, as you read and is outlined in the subscription agreement. I’ve also double-checked with WeFunder regarding your specific issue with receipt, and they’re making/made all necessary internal adjustments on their end. Rest assured, everything will reflect accurately moving forward."},{"question":"Regarding the use of funds, I note intended funds to be repaid to management. At this early stage of the game I question why I should enter as others exit at $10.51 that have considerably more knowledge than supplied, at a buck might be worth a shot. Anything else to consider ?","answer":"Thank you for your question, Roger, and for taking the investment process seriously—your diligence embodies the thoughtful approach we value in investors. No one from management is selling shares into this round or exiting their positions to profit personally on the current raise. Every dollar raised is being reinvested to further the company, accelerate product development, and drive valuation growth for all shareholders. At this stage, selling shares for the specific purpose of taking money..."}]}}}